



**University of
Zurich^{UZH}**

**Zurich Open Repository and
Archive**

University of Zurich
University Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch

Year: 2010

Targeting integrins in malignant glioma

Tabatabai, G ; Weller, M ; Nabors, B ; Picard, M ; Reardon, D ; Mikkelsen, T ; Ruegg, C ; Stupp, R

Abstract: The integrin family of cell adhesion receptors is emerging as a promising target of anticancer therapy. AlphaVbeta3 and alphaVbeta5 integrins are overexpressed on both glioma cells and tumor vasculature. Cilengitide, the most advanced specific integrin inhibitor in oncology, has shown antitumor activity against glioma in early clinical trials. Durable remissions have been observed in phase I and phase II trials for recurrent glioblastoma (GBM) with both lower and higher doses of cilengitide. Pilot trials in newly diagnosed glioblastoma in conjunction with standard chemoradiotherapy have been encouraging. Preclinical data suggest synergy with concomitant chemo- and radiation therapy. A pivotal phase III study (CENTRIC) in newly diagnosed GBM patients is currently recruiting. This paper summarizes the current understanding of the role of integrins and their inhibition in gliomagenesis. The background and design of ongoing trials are outlined.

DOI: <https://doi.org/10.1007/s11523-010-0156-3>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-35964>

Journal Article

Published Version

Originally published at:

Tabatabai, G; Weller, M; Nabors, B; Picard, M; Reardon, D; Mikkelsen, T; Ruegg, C; Stupp, R (2010). Targeting integrins in malignant glioma. *Targeted Oncology*, 5(3):175-181.

DOI: <https://doi.org/10.1007/s11523-010-0156-3>

Targeting integrins in malignant glioma

Ghazaleh Tabatabai · Michael Weller · Burt Nabors ·
Martin Picard · David Reardon · Tom Mikkelsen ·
Curzio Ruegg · Roger Stupp

Received: 11 August 2010 / Accepted: 12 August 2010 / Published online: 4 September 2010
© Springer-Verlag 2010

Abstract The integrin family of cell adhesion receptors is emerging as a promising target of anticancer therapy. AlphaVbeta3 and alphaVbeta5 integrins are overexpressed on both glioma cells and tumor vasculature. Cilengitide, the most advanced specific integrin inhibitor in oncology, has shown antitumor activity against glioma in early clinical trials. Durable remissions have been observed in phase I and phase II trials for recurrent glioblastoma (GBM) with both lower and higher doses of cilengitide. Pilot trials in newly diagnosed glioblastoma in conjunction with standard chemoradiotherapy have been encouraging. Preclinical data suggest synergy with concomitant chemo- and radiation therapy. A pivotal phase III study (CENTRIC) in newly diagnosed GBM patients is currently recruiting. This paper

summarizes the current understanding of the role of integrins and their inhibition in gliomagenesis. The background and design of ongoing trials are outlined.

Keywords Integrins · Angiogenesis · Glioma · Glioblastoma · Clinical trials · Review

Introduction

Integrins are heterodimeric transmembrane cell surface receptors that play a key role in the crosstalk between the cell and its surrounding stroma [1]. Twenty-four different integrins have been identified to date. Integrins link the

G. Tabatabai (✉) · M. Weller
Department of Neurology, University Hospital Zurich,
Frauenklinikstrasse 26,
8091 Zurich, Switzerland
e-mail: ghazaleh.tabatabai@usz.ch

M. Weller
e-mail: michael.weller@usz.ch

B. Nabors
Department of Neurology, University of Alabama at Birmingham,
Birmingham, AL, USA

M. Picard
Global Clinical Development Unit Oncology, Merck KGaA,
Frankfurter Strasse 250,
64293 Darmstadt, Germany

D. Reardon
Departments of Surgery and Pediatrics, The Preston Robert Tisch
Brain Tumor Center, Duke University Medical Center,
Durham, NC, USA

T. Mikkelsen
Department of Neurosurgery, Hermelin Brain Tumor Center,
Henry Ford Hospital,
Detroit, MI, USA

T. Mikkelsen
Department of Neurology, Hermelin Brain Tumor Center,
Henry Ford Hospital,
Detroit, MI, USA

C. Ruegg
Division of Experimental Oncology, Centre Pluridisciplinaire
d'Oncologie, Faculty of Biology and Medicine,
University of Lausanne, and NCCR Molecular Oncology
ISREC-EPFL,
Epalinges, Switzerland

C. Ruegg
Pathology, Med3, Department of Medicine, Faculty of Science,
University of Fribourg,
Fribourg, Switzerland

R. Stupp (✉)
Department of Neurosurgery, Centre Hospitalier Universitaire
Vaudois (CHUV) and University of Lausanne,
Lausanne, Switzerland
e-mail: roger.stupp@chuv.ch

cytoskeleton to the extracellular matrix, and are recognized to be key regulators of tissue structure. Integrins regulate cell adhesion, migration, differentiation, proliferation, and survival during physiological and pathological conditions, including inflammation and cancer. Upon ligation to extracellular ligands (i.e., matrix proteins such as collagens, laminins, vitronectins and fibronectins), integrins activate downstream signaling pathways in concert with growth factor receptors, including platelet-derived growth factor receptor (PDGFR), epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR).

Preclinical data indicate that integrins play a key role in cancer initiation and progression [2]. They provide adhesive, migratory, and survival cues to tumor cells and to cells of the tumor microenvironment, including angiogenic endothelial cells. The integrins α V β 3 and α V β 5, among others, are highly expressed not only on the tumor vasculature and angiogenic endothelial cells, but also on tumor cells, including gliomas (reviewed in [3, 4]). Consequently, integrins have been considered as a promising therapeutic target in cancer [5]. Monoclonal antibodies and peptide-based integrin inhibitors are being investigated for their potential therapeutic activity in various tumor types. This strategy is in advanced stage clinical development in glioblastoma, a highly vascular primary brain tumor. The only integrin inhibitor being studied in glioma is cilengitide, we therefore focus this short review on this agent.

Preclinical data on integrins in glioma

In high-grade glioma, and in particular in glioblastoma, overexpression of α V β 3 integrin is well documented. Importantly, α V β 3 integrin is expressed both on angiogenic endothelial cells and on tumor cells [6–8]. Molecular imaging of α V β 3 expression using the tracer [18F]Galacto-RGD and validation by immunohistochemistry revealed that α V β 3 integrin expression was mainly confined to the tumor region and was absent in normal tissue [9]. Selective α V β 3 upregulation in malignant gliomas suggests that integrin signaling in glioblastoma has important functions. Emerging evidence indicates that integrins promote glioblastoma adhesion, migration and angiogenesis [10, 11]. In an autocrine loop hypoxia will recruit α V β 3 and α V β 5 integrins and activate focal adhesion kinase (FAK). Integrin inhibition decreases hypoxia-inducible factor 1 α (HIF-1 α) and reduces thus tumor hypoxia, which may lead to increased radiation sensitivity [12].

The integrin α 6 β 1 plays an important role for the regulation of glioma-initiating cells in the perivascular

niche [13]. This integrin mediates the interaction of glioma-initiating cells to laminin, an extracellular matrix protein expressed in basement membranes, including those supporting endothelial cells. This interaction provides an anchorage for glioma-initiating cells within the perivascular niche and supports their tumorigenic potential.

Given the role of integrins in promoting glioma growth, invasion and angiogenesis, integrin inhibitors might be ideal therapeutic tools with synergistic activities in conjunction with already established therapeutic modalities, i.e., radiation therapy and cytotoxic chemotherapy. Importantly, because of their antiangiogenic effects [14], integrin inhibitors are expected to normalize the tumor vasculature, which in turn might enhance the effects of radiation therapy and chemotherapy. Indeed the efficacy of these two therapeutic modalities depends on an effective blood perfusion for oxygenation of the tumor (i.e., an important condition for radiation-induced tumor cell killing) and optimal drug delivery. Inhibition of α V β 3 and α V β 5 integrins in hypoxic glioma cells by siRNA decreases HIF-1 α by regulating FAK. Silencing this signaling cascade in established xenografts indeed reduced hypoxia and decreased angiogenesis [12].

Interestingly, ionizing radiation induces ceramide-mediated apoptosis of tumor endothelial cells, causing tumor vessel disruption and delayed tumor growth [15]. Consistent with a cytotoxic effect of radiotherapy on angiogenic vessels, concomitant administration of antiangiogenic drugs decreases endothelial cell survival. Anti-VEGF antibodies (e.g., bevacizumab) [16], VEGFR inhibitors (e.g., AG-013736) [17], mTOR inhibitors (e.g., RAD001) [18], and integrin inhibition (cilengitide) [19] sensitize angiogenic endothelial cells to ionizing radiation-induced death, thereby enhancing tumor vascular damage induced by radiotherapy and improving therapeutic response [20]. Irradiation of glioma cells increases their expression of α V β 3 integrin [21], thus integrin inhibition will further synergize with radiation therapy.

Regarding clinical translation, targeting α V β 3 and α V β 5 might reduce hypoxia and thus resistance to radio- and/or chemotherapy [12]. Indeed, arresting integrin signaling synergistically enhances the anti-glioma effect of radiation therapy in vivo [22].

A recent preclinical study suggests that low concentrations of small molecular integrin inhibitors used as single agents may stimulate angiogenesis and tumor growth in experimental melanoma and Lewis Lung carcinoma models, through increased VEGF expression and VEGFR2 signaling [23]. The concentrations of the small molecular integrin inhibitor cilengitide, measured in patients in clinical trials, however, largely exceed the critical “proangiogenic” concentrations described in this preclinical study, and therefore, paradoxical proangiogenic effects of small

molecular integrin inhibitors in the clinical application seem rather unlikely [24]. In fact, relative cerebral blood volume and blood flow, measured by perfusion MRI, remained stable or decreased among recurrent GBM patients responding to cilengitide therapy in a prior phase I study [25]. Durable and clinically relevant responses have been observed with cilengitide monotherapy; ongoing clinical studies administer cilengitide in combination with radiotherapy and/or chemotherapy. Nevertheless, the durable therapeutic success will depend on the efficient management of escape mechanisms occurring under anti-integrin therapies [26, 27].

Integrin inhibition attenuates invasion and metastasis secondary to radiation-induced angiogenesis inhibition

Vascular normalization may not be the only mechanism by which integrin inhibitors synergize with radio-chemotherapy. We have recently observed that high doses of ionizing radiation locally suppress angiogenesis *in vivo* and inhibited endothelial cell sprouting *in vitro* through a cell-autonomous effect mediated by the TGF β receptor ALK5 [28]. Tumors derived from oral squamous cell carcinoma and from hepatoma cell lines growing within a pre-irradiated bed had decreased microvascular density and were smaller, but their margins were highly invasive. They also had increased hypoxia and necrosis, and a more aggressive behavior with a higher number of lung metastases [29]. Thus, pre-irradiation of the tumor bed reduces local tumor growth, likely due to acute metabolic starvation secondary to suppressed angiogenesis, but at the same time it may enhance local invasion and metastatic spreading, possibly through increased hypoxia. We have identified the cysteine-rich protein 61 (CYR61), a member of the CCN (CYR61/CTGF/NOV) family of matricellular proteins regulating cell growth, differentiation, survival and migration in development, tissue remodeling and repair [30], and integrin α V β 5 (a receptor for CYR61) expressed by tumor cells, as critical molecules that cooperate to promote local invasion and distant metastases [29]. Importantly, function-blocking anti- α V mAb 17E6 [29, 31] and cilengitide-inhibited CYR61-mediated invasion and metastasis formation of tumor cells growing in a pre-irradiated bed. These results suggest that cilengitide may improve cancer control in conjunction with radiotherapy by attenuating some of the unwanted rebound effect of radiation-induced inhibition of angiogenesis. Hypoxia is well known to activate pro-invasive programs [32] and select for resistant variants with invasive characteristics. This view is consistent with a recent experimental study demonstrating that selected inhibition of tumor angiogenesis by antiangiogenic drugs, including in experimental

glioma, results in increased invasion and metastasis formation [33].

Cilengitide

Cilengitide (Merck KGaA, Darmstadt, Germany) is a synthetic Arg-Gly-Asp (RGD) pentapeptide recognizing the RGD ligand-binding motif (ligand binding site) on the integrin receptors α V β 3 and α V β 5 [34, 35] and competitively blocks integrin ligand binding. It was shown to diminish angiogenesis *in vitro* [36]. In an important early preclinical study, cilengitide markedly suppressed tumor growth in a medulloblastoma and orthotopic glioblastoma models (i.e., tumors were grown in the brain), while no growth inhibition was demonstrated in a heterotopic model (i.e., when tumors were grown in the flank of nude mice), or when an inactive peptide was used [37]. This suggests that the brain environment is particularly susceptible to integrin inhibition and led to subsequent clinical investigation.

In phase I studies cilengitide was administered twice weekly by intravenous infusion over 1 h. No dose limiting toxicity was observed with doses up to 2400 mg/m². Peak plasma concentrations that had shown antitumor effects in preclinical models were achieved at doses ≥ 120 mg/m² [25, 38–40]. The terminal half-life of cilengitide is 3–5 h, suggesting the possibility of increased efficacy with a more frequent administration or continuous infusion schedule.

Clinical experience with cilengitide in malignant glioma

Sustained responses in recurrent glioblastoma were seen both with lower and higher doses of cilengitide as single agent in two phase I trials in adult and pediatric patients [25, 39]. Overall cilengitide was well tolerated, a maximal tolerated dose not reached and a clinical benefit seen both at higher and lower doses. Subsequent trials were initiated with flat (not per m²) twice weekly dosing of cilengitide at an intermediate lower (500 mg) and intermediate higher (2000 mg) dose (Table 1). In a randomized phase II trial of 81 patients with recurrent glioblastoma, treatment was administered at the lower and higher dose. Cilengitide monotherapy was well tolerated independently of the dose. Objective responses were achieved in 5% or 13% of patients treated with 500 mg or 2000 mg, respectively. Progression-free survival after 6 months was 10% and 15%, whereas overall survival was in the range of 6.5 versus 9.9 months, respectively [41]. Recently, long-term survival results were reported demonstrating a 4-year survival rate of 2.4% (95%CI 0.2; 11%) in patients treated with the lower dose, and 10.0% (95%CI 3.2; 21.5%) in patients

Table 1 Completed trials of cilengitide in primary brain tumors

Author/year (trial#)	Trial design/number of patients	Cilengitide dose ^a	Disease setting	Main results
Nabors/2007 (NABTT9911) [25]	Phase I, 51 patients (38 with GBM)	Single agent 120–2400 mg/m ²	Recurrent malignant gliomas	No DLT and MTD; no bleeding events 2 CR (1 GBM, 1 AA) lasting 12 + 24+ months 3 PR (mean duration of 9.3 months), 16 SD (mean duration of 5.4 months) No MTD; intratumoral hemorrhage (asymptomatic, grade 1 in 2, grade 3 in 1 patient at 2400 mg/m ² dose level). 1 CR (GBM, lasting >1 year) 6 SD (lasting >1 year in 3 pts)
MacDonald/2008 (PBT012) [39]	Phase I, 31 patients	Single agent 120–2400 mg/m ²	Pediatric refractory gliomas, meningiomas, and PNET	No bleeding complications, no wound healing complications in subsequent surgery Cilengitide detected in all tumor samples, trend to higher tumor exposure with higher dose. PFS-6 12%
Gilbert/2008 (NABTC 03-02) [44]	Translational phase II, 30 GBM patients	Single agent 3 doses (500 mg or 2000 mg) preop. until day -1. Postop. therapy at 2000 mg	Recurrent glioblastoma planned for second surgery	500 mg: RR 5%; PFS-6 10% (CI 3–24); median OS 6.5 (CI 5–9); 2000 mg: RR 13%, PFS-6 15% (CI 6–30), median OS 9.9 months (CI 6–16) median OS 18.9 months (CI 17–22), median OS for 500 mg cohort: ~17 months median OS for 2000 mg cohort: ~21 months Median PFS 8 months (CI 6–11) PFS at 6 or 12 mo: 69% (CI 54–80); 33% (CI 21–46) Median OS 16.1 months (CI 13–23) Survival at 2 years: 35% (CI 22–48)
Reardon/2008 (EMD009) [41]	Randomized phase II, 81 GBM patients	Single agent 500 mg versus 2000 mg	Recurrent GBM (first recurrence after TMZ/RT failure, measurable disease)	
Nabors 2009 (NABTT0306) [43]	Randomized phase II 112 GBM patients	500 mg versus 2000 mg in combination with TMZ/RT→TMZ	Newly diagnosed GBM	
Stupp/2010 (EMD010) [45]	Phase I/IIa 52 GBM patients	500 mg in combination with TMZ/RT→TMZ	Newly diagnosed GBM	

^a Cilengitide dose administered twice weekly i.v. over 60 min

DLT dose-limiting toxicity, MTD maximally tolerated dose, CR complete response, PR partial response, SD stable disease, GBM glioblastoma, AA anaplastic astrocytoma, PNET primitive neuroectodermal tumor, CI 95% confidence interval, PFS progression-free survival, PFS-6 progression-free survival rate at 6 months, OS overall survival, TMZ/RT→TMZ concomitant chemoradiotherapy with temozolomide, followed by adjuvant temozolomide [46], NABTT New Approaches to Brain Tumor Therapy, NABTC North American Brain Tumor Consortium, PBT Pediatric Brain Tumor Consortium, EMD Merck Serono

treated with the higher dose of cilengitide [42]. Similarly, a phase II randomized trial evaluating lower (500 mg) and higher (2000 mg) doses cilengitide added to temozolomide and radiotherapy (TMZ/RT) in newly diagnosed glioblastoma patients was reported in abstract form [43]. Median survival was 18.9 months, with an estimated median survival of 17 months and 21 months, for the lower and higher dose, respectively. Finally, higher exposure of the tumor tissue could be demonstrated in another randomized trial evaluating 3 doses of either 500 mg or 2000 mg cilengitide prior to tumor resection in recurrent disease. Cilengitide concentrations were several-fold higher in the tumor than the corresponding plasma concentrations, demonstrating both excellent penetration through the blood-tumor barrier and retention within the tumor. Importantly, safety could be confirmed and no increase in bleeding complications or wound healing problems were observed [44].

Consistently, the higher dose of cilengitide is favored by exposure, responses, progression-free and overall survival.

Based on a strong preclinical rationale of radiosensitization and synergy with both cilengitide and irradiation and TMZ, we designed in parallel to the above-mentioned trials a phase II pilot trial of adding cilengitide (500 mg) to standard chemoradiotherapy with TMZ (TMZ/RT→TMZ) [45, 46].

In a multicenter pilot study on 52 patients, treatment was well tolerated with no identifiable added toxicity. The primary endpoint of progression-free survival at 6 months compared favorably with historical controls (69% versus 54%) [46, 47]. Median survival was 16.1 months, with a 2-year survival rate of 35% [45]. Interestingly, the outcome was particularly good in patients with a methylated O⁶-methylguanine–DNA methyltransferase (*MGMT*) gene promoter. Such patients were previously identified to particularly benefit from TMZ chemotherapy [48]. This is consistent with the working hypothesis, that antiangiogenic therapy may lead to normalization of tumor vasculature, decrease of hypoxia, improved drug delivery and enhanced cytotoxicity. In addition, the currently used higher dose of 2000 mg should also exert relevant direct antitumor activity and directly synergize with standard chemoradiotherapy.

Building on our pilot experience and the consistent encouraging results of the other clinical trials in malignant glioma, Merck KGaA in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) and the Canadian Brain Tumor Consortium is sponsoring a large prospective clinical phase III trial (CENTRIC study, Fig. 1) [49]. Based on the suggested synergy between normalized perfusion and active chemotherapy, only patients with a methylated *MGMT* are eligible.

This requires centralized upfront *MGMT* testing, and it is the first prospective international clinical oncology trial incorporating this novel molecular marker to homogeneously define the treated patient population. Other changes from the previous phase II trial are the exclusive use of the higher dose of cilengitide (2000 mg), and cilengitide maintenance therapy for up to 18 months. In parallel a separate 3-arm randomized phase II trial has been designed for patients with *MGMT* unmethylated tumors (CORE study). Here an intensified high-dose daily cilengitide administration before radiotherapy is being explored. Early data indicate that this schedule is well tolerated and safe, and the trial is now ongoing in a multicenter setting. The results of all completed brain tumor clinical trials using cilengitide are summarized in Table 1.

Conclusions

The ongoing phase III CENTRIC trial is successfully recruiting in a multi-national setting and is expected to be completed by the end of the year 2010. Careful analysis of data emerging from this trial will make an important contribution to further defining the role on integrin inhibition in malignant gliomas. The absence of significant toxicity and excellent tolerance will allow to safely testing integrin-inhibition in combination with other targeted and cytotoxic agents. Combined inhibition of integrins and VEGF may lead to further enhancement and increased antitumor effect, and clinical evaluation of this concept is warranted.

Conflict of interest statement The authors have no significant conflict of interest to declare. The paper was written by G. Tabatabai and R. Stupp, with review, input, comments and final approval by all authors. The authors have conducted and are conducting industry and/or NCI-sponsored trials with cilengitide.

References

1. Takada Y, Ye X, Simon S (2007) The integrins. *Genome Biol* 8 (5):215. doi:10.1186/gb-2007-8-5-215
2. Desgrosellier JS, Cheresh DA (2010) Integrins in cancer: biological implications and therapeutic opportunities. *Nat Rev Cancer* 10(1):9–22. doi:10.1038/nrc2748
3. Ruegg C, Mariotti A (2003) Vascular integrins: pleiotropic adhesion and signaling molecules in vascular homeostasis and angiogenesis. *Cell Mol Life Sci* 60(6):1135–1157
4. Avraamides CJ, Garmy-Susini B, Varner JA (2008) Integrins in angiogenesis and lymphangiogenesis. *Nat Rev Cancer* 8(8):604–617. doi:10.1038/nrc2353
5. Alghisi GC, Ruegg C (2006) Vascular integrins in tumor angiogenesis: mediators and therapeutic targets. *Endothelium* 13 (2):113–135
6. Schnell O, Krebs B, Wagner E, Romagna A, Beer AJ, Grau SJ, Thon N, Goetz C, Kretzschmar HA, Tonn JC, Goldbrunner RH

- (2008) Expression of integrin alphavbeta3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature. *Brain Pathol* 18(3):378–386. doi:10.1111/j.1750-3639.2008.00137.x
7. Taga T, Suzuki A, Gonzalez-Gomez I, Gilles FH, Stins M, Shimada H, Barsky L, Weinberg KI, Laug WE (2002) Alpha v-integrin antagonist emd 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. *Int J Cancer* 98(5):690–697. doi:10.1002/ijc.10265
 8. Bello L, Francolini M, Marthyn P, Zhang J, Carroll RS, Nikas DC, Strasser JF, Villani R, Cheresch DA, Black PM (2001) Alpha(v) beta3 and alpha(v)beta5 integrin expression in glioma periphery. *Neurosurgery* 49(2):380–389, discussion 390
 9. Beer AJ, Haubner R, Sarbia M, Goebel M, Luderschmidt S, Grosu AL, Schnell O, Niemeyer M, Kessler H, Wester HJ, Weber WA, Schwaiger M (2006) Positron emission tomography using [18f]galacto-rgd identifies the level of integrin alpha(v)beta3 expression in man. *Clin Cancer Res* 12(13):3942–3949. doi:10.1158/1078-0432.CCR-06-0266
 10. Wild-Bode C, Weller M, Wick W (2001) Molecular determinants of glioma cell migration and invasion. *J Neurosurg* 94(6):978–984. doi:10.3171/jns.2001.94.6.0978
 11. Maurer GD, Tritschler I, Adams B, Tabatabai G, Wick W, Stupp R, Weller M (2009) Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. *Neuro Oncol* 11(6):747–756. doi:10.1215/15228517-2009-012
 12. Skuli N, Monferran S, Delmas C, Favre G, Bonnet J, Toulas C, Cohen-Jonathan Moyal E (2009) Alphavbeta3/alphavbeta5 integrins-fak-rhoB: a novel pathway for hypoxia regulation in glioblastoma. *Cancer Res* 69(8):3308–3316. doi:10.1158/0008-5472.CAN-08-2158
 13. Lathia JD, Gallagher J, Heddleston JM, Wang J, Eyler CE, Macsworlds J, Wu Q, Vasanji A, McLendon RE, Hjelmeland AB, Rich JN (2010) Integrin alpha 6 regulates glioblastoma stem cells. *Cell Stem Cell* 6(5):421–432. doi:10.1016/j.stem.2010.02.018
 14. Ruegg C, Alghisi GC (2010) Vascular integrins: therapeutic and imaging targets of tumor angiogenesis. *Recent Results Cancer Res* 180:83–101. doi:10.1007/978-3-540-78281-0_6
 15. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, Fuks Z, Kolesnick R (2003) Tumor response to radiotherapy regulated by endothelial cell apoptosis. *Science* 300(5622):1155–1159. doi:10.1126/science.1082504300/5622/1155
 16. Nieder C, Wiedenmann N, Andratschke NH, Astner ST, Molls M (2007) Radiation therapy plus angiogenesis inhibition with bevacizumab: rationale and initial experience. *Rev Recent Clin Trials* 2(3):163–168
 17. Fenton BM, Paoni SF (2007) The addition of ag-013736 to fractionated radiation improves tumor response without functionally normalizing the tumor vasculature. *Cancer Res* 67(20):9921–9928. doi:10.1158/0008-5472.CAN-07-1066
 18. Shinohara ET, Cao C, Niernann K, Mu Y, Zeng F, Hallahan DE, Lu B (2005) Enhanced radiation damage of tumor vasculature by mtor inhibitors. *Oncogene* 24(35):5414–5422. doi:10.1038/sj.onc.1208715
 19. Albert JM, Cao C, Geng L, Leavitt L, Hallahan DE, Lu B (2006) Integrin alpha v beta 3 antagonist cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models. *Int J Radiat Oncol Biol Phys* 65(5):1536–1543. doi:10.1016/j.ijrobp.2006.04.036
 20. Wachsberger P, Burd R, Dicker AP (2004) Improving tumor response to radiotherapy by targeting angiogenesis signaling pathways. *Hematol Oncol Clin North Am* 18(5):1039–1057. doi:10.1016/j.hoc.2004.06.007, viii
 21. Wild-Bode C, Weller M, Rimner A, Dichgans J, Wick W (2001) Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. *Cancer Res* 61(6):2744–2750
 22. Mikkelsen T, Brodie C, Finniss S, Berens ME, Rennert JL, Nelson K, Lemke N, Brown SL, Hahn D, Neuteboom B, Goodman SL (2009) Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency. *Int J Cancer* 124(11):2719–2727. doi:10.1002/ijc.24240
 23. Reynolds AR, Hart IR, Watson AR, Welti JC, Silva RG, Robinson SD, Da Violante G, Gourlaouen M, Salih M, Jones MC, Jones DT, Saunders G, Kostourou V, Perron-Sierra F, Norman JC, Tucker GC, Hodivala-Dilke KM (2009) Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. *Nat Med* 15(4):392–400. doi:10.1038/nm.1941
 24. Weller M, Reardon D, Nabors B, Stupp R (2009) Will integrin inhibitors have proangiogenic effects in the clinic? *Nat Med* 15(7):726. doi:10.1038/nm0709-726, author reply 727
 25. Nabors B, Mikkelsen T, Rosenfeld S, Hochberg F, Shastri Akella N, Fisher J, Cloud G, Zhang Y, Carson K, Wittemer S, Colvevas D, Grossman S, for the NABTT CNS Consortium (2007) A phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. *J Clin Oncol* 25(13):1651–1657
 26. Abdollahi A, Griggs DW, Zieher H, Roth A, Lipson KE, Saffrich R, Grone HJ, Hallahan DE, Reisfeld RA, Debus J, Niethammer AG, Huber PE (2005) Inhibition of alpha(V)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. *Clin Cancer Res* 11(17):6270–6279
 27. Abdollahi A, Folkman J (2010) Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. *Drug Resist Updat* 13(1–2):16–28. doi:10.1016/j.drug.2009.12.001
 28. Imaizumi N, Monnier Y, Hegi M, Mirimanoff RO, Ruegg C (2010) Radiotherapy suppresses angiogenesis in mice through tgfbeta1/alk5-dependent inhibition of endothelial cell sprouting. *PLoS ONE* 5(6):e11084. doi:10.1371/journal.pone.0011084
 29. Monnier Y, Farmer P, Bieler G, Imaizumi N, Sengstag T, Alghisi GC, Stehle JC, Ciarloni L, Andrejevic-Blant S, Moeckli R, Mirimanoff RO, Goodman SL, Delorenzi M, Ruegg C (2008) Cyr61 and alphaVbeta5 integrin cooperate to promote invasion and metastasis of tumors growing in preirradiated stroma. *Cancer Res* 68(18):7323–7331. doi:10.1158/0008-5472.CAN-08-0841
 30. Leask A, Abraham DJ (2006) All in the ccn family: essential matricellular signaling modulators emerge from the bunker. *J Cell Sci* 119(Pt 23):4803–4810. doi:10.1242/jcs.03270
 31. Mitjans F, Sander D, Adan J, Sutter A, Martinez JM, Jaggle CS, Moyano JM, Kreysch HG, Piulats J, Goodman SL (1995) An anti-alpha V-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice. *J Cell Sci* 108(Pt 8):2825–2838
 32. Chan DA, Giaccia AJ (2007) Hypoxia, gene expression, and metastasis. *Cancer Metastasis Rev* 26(2):333–339. doi:10.1007/s10555-007-9063-1
 33. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. *Cancer Cell* 15(3):220–231. doi:10.1016/j.ccr.2009.01.027
 34. Xiong JP, Stehle T, Zhang R, Joachimiak A, Frech M, Goodman SL, Arnaout MA (2002) Crystal structure of the extracellular segment of integrin alphaVbeta3 in complex with an arg-gly-aspartic ligand. *Science* 296(5565):151–155. doi:10.1126/science.1069040
 35. Goodman SL, Holzemann G, Sulyok GA, Kessler H (2002) Nanomolar small molecule inhibitors for alphaV(beta)6, alphaV(beta)5, and alphaV(beta)3 integrins. *J Med Chem* 45(5):1045–1051. doi:10.1021/jm0102598
 36. Nisato RE, Tille JC, Jonczyk A, Goodman SL, Pepper MS (2003) AlphaV beta 3 and alphav beta 5 integrin antagonists inhibit

- angiogenesis in vitro. *Angiogenesis* 6(2):105–119. doi:[10.1023/B:AGEN.0000011801.98187.f25255607](https://doi.org/10.1023/B:AGEN.0000011801.98187.f25255607)
37. MacDonald TJ, Taga T, Shimada H, Tabrizi P, Zlokovic BV, Cheresch DA, Laug WE (2001) Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(V) integrin antagonist. *Neurosurgery* 48(1):151–157
 38. Eskens FA, Dumez H, Hoekstra R, Perschl A, Brindley C, Bottcher S, Wynendaale W, Drevs J, Verweij J, van Oosterom AT (2003) Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. *Eur J Cancer* 39(7):917–926. doi:[S0959804903000571](https://doi.org/S0959804903000571)
 39. MacDonald TJ, Stewart CF, Kocak M, Goldman S, Ellenbogen RG, Phillips P, Lafond D, Poussaint TY, Kieran MW, Boyett JM, Kun LE (2008) Phase I clinical trial of cilengitide in children with refractory brain tumors: pediatric brain tumor consortium study pbtcc-012. *J Clin Oncol* 26(6):919–924. doi:[10.1200/JCO.2007.14.1812](https://doi.org/10.1200/JCO.2007.14.1812)
 40. Stupp R, Ruegg C (2007) Integrin inhibitors reaching the clinic. *J Clin Oncol* 25(13):1637–1638
 41. Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O'Neill A, Plotkin S, Glantz M, Ravin P, Raizer JJ, Rich KM, Schiff D, Shapiro WR, Burdette-Radoux S, Dropcho EJ, Wittemer SM, Nippgen J, Picard M, Nabors LB (2008) Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. *J Clin Oncol* 26(34):5610–5617. doi:[10.1200/JCO.2008.16.7510](https://doi.org/10.1200/JCO.2008.16.7510)
 42. Fink K, Mikkelsen T, Nabors LB, Ravin P, Plotkin SR, Schiff D, Hicking C, Picard M, Reardon DA (2010) Long-term effects of cilengitide, a novel integrin inhibitor, in recurrent glioblastoma: a randomized phase IIa study. *Proc Am Soc Clin Oncol, J Clin Oncol* 28(suppl):15s, abstract 2010
 43. Nabors L, Mikkelsen T, Batchelor T, Lesser G, Rosenfeld M, Ye X, Piantadosi S, Olson J, Brem S, Grossman S (2009) Nabtt 0306: A randomized phase II trial of EMD 121974 in conjunction with concomitant and adjuvant temozolomide with radiation therapy in patients with newly diagnosed glioblastoma multiforme (GBM). *Proc Am Soc Clin Oncol, J Clin Oncol* 27:15s, suppl; abstract 2001
 44. Gilbert M, Lamborn K, Lassman A, Cloughesy T, Chang S, Lieberman F, Wen P, Poetzsch S, Picard M, Prados M, Kuhn J, for the North American Brain Tumor Consortium (2007) Tumor tissue delivery of cilengitide after intravenous administration to patients with recurrent glioblastoma. Preliminary data from NABTC protocol 03–02. *Neuro Oncol* 4:525
 45. Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PM, Grabenbauer GG, Ochsenbein AF, Simon M, Dietrich PY, Pietsch T, Hicking C, Tonn JC, Diserens AC, Pica A, Hermisson M, Krueger S, Picard M, Weller M (2010) Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. *J Clin Oncol* 28(16):2712–2718. doi:[10.1200/JCO.2009.26.6650](https://doi.org/10.1200/JCO.2009.26.6650)
 46. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N Engl J Med* 352(10):987–996
 47. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. *Lancet Oncol* 10(5):459–466. doi:[10.1016/S1470-2045\(09\)70025-7](https://doi.org/10.1016/S1470-2045(09)70025-7)
 48. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. *N Engl J Med* 352(10):997–1003
 49. Stupp R, Van Den Bent MJ, Erridge SC, Reardon DA, Hong Y, Wheeler H, Hegi M, Perry JR, Picard M, Weller M (2010) Cilengitide in newly diagnosed glioblastoma with MGMT promoter methylation: protocol of a multicenter, randomized, open-label, controlled phase III trial (CENTRIC). *Proc Am Soc Clin Oncol, J Clin Oncol* 28:15s, suppl; abstr TPS152